Gapping down
In reaction to disappointing earnings/guidance:
- FDX -7.7%
M&A news:
- FCAU -0.9% (Fiat Chrysler and Peugeot (PEUGF) agree to merge)
Other news:
- ADRO -14.8% (NVS removes ADU-S100 from its portfolio)
- FIXX -14% (announces clinical data from Phase 1/2 pheNIX gene therapy trial for PKU)
- PACB -6.5% (FTC challenges ILMN proposed acquisition of PACB)
- ANH -6.2% (lowers dividend)
- CFMS -5.5% (received FDA warning letter that concerns the number of sterilization cycle failures relating to Vaporized Hydrogen Peroxide sterilizers that the Company uses) JNCE -4.7% (enters into $50 mln stock sales agreement)
- CNST -4.4% (files for ~7.6 mln share common stock shelf offering by selling shareholders )
- EPZM -3.8% (confirms trading of stock halted; Oncology Drug Advisory Committee to review tazemetostat at 8:00 a.m. ET today for the treatment of patients with metastatic or locally advanced epithelioid sarcoma)
- GBT -1.4% (entered into $150 mln non-dilutive loan agreement with funds managed by Pharmakon Advisors and manager of the BioPharma Credit funds)
- QIWI -1.3% (announces resignation of Sergey Solonin as CEO, effective January 15; appoints Boris Kim as next CEO)
Analyst comments:
- AMC -2.7% (downgraded to Underperform from Neutral at BofA/Merrill)
- DPZ -1.3% (downgraded to Neutral from Buy at Longbow)
- HAL -1% (downgraded to Market Perform from Outperform at BMO Capital Markets)